When an adverse event report involves a counterfeit product, the company should: Response:

Question

Options

• AIgnore the report, as it does not involve a genuine product.
• BInform regulatory authorities and possibly issue a public warning to prevent further harm.
• COnly inform the direct customers about the counterfeit product.
• DConsider the event as a minor issue that does not require action.

• A
  3% (1)
• B
  79% (30)
• C
  8% (3)
• D
  11% (4)

Explanation

Option B is correct because counterfeit products pose a serious public health risk - other consumers may still be using the same counterfeit product, and regulatory authorities must be notified so they can investigate, track the source, and coordinate a broader response. Ignoring the report (A) violates pharmacovigilance obligations and leaves other patients at risk, making inaction legally and ethically unacceptable. Notifying only direct customers (C) is insufficient because counterfeits often circulate through multiple uncontrolled channels, and a public warning may be necessary to reach all affected parties. Treating it as a minor issue (D) is dangerous - counterfeits can contain wrong ingredients, incorrect doses, or contaminants that cause serious harm.

Memory tip: Think "counterfeit = public threat." Whenever a product safety issue extends beyond your immediate customer base, the response must scale accordingly - regulators + public warning, not silence or limited disclosure.

No community discussion yet for this question.